Mon Nov 03 11:40:00 UTC 2025: Here’s a summary of the text and a rewritten version as a news article:
Summary:
Analysts are lowering their price targets for Kenvue Inc. (KVUE), a consumer health company with brands like Aveeno and Tylenol. Jefferies reduced its target due to weak retail trends and ongoing legal challenges in the UK related to talc products. Deutsche Bank also lowered its target. Despite the downgrades, Jefferies maintains a “Buy” rating, expecting the company’s 2025 guidance to remain intact and believes upcoming announcements regarding a new CEO and strategic review could be significant. The article contrasts Kenvue with potentially higher-growth AI stocks.
News Article:
Kenvue Stock Target Prices Slashed Amid Retail Weakness and Legal Woes
NEW YORK – Kenvue Inc. (NYSE:KVUE), the consumer health giant behind brands like Aveeno and Tylenol, is facing headwinds as analysts revise down their stock price targets. Jefferies recently lowered its target from $25 to $23, citing signs of weakening retail trends – a 1.5% drop representing a 100 basis point reduction quarter-over-quarter. The firm also pointed to ongoing legal challenges in the United Kingdom concerning allegations that Kenvue’s talc products cause cancer.
“The lower price target accounts for lower visibility into turnaround timing, given liability risk,” said Jefferies in a note to investors. Despite the downgrade, the firm maintains a “Buy” rating, expressing confidence in Kenvue’s ability to meet its 2025 guidance. Jefferies anticipates that upcoming announcements regarding the appointment of a permanent CEO and updates on the company’s strategic review will be crucial for investor sentiment.
This follows a similar move by Deutsche Bank on October 24th, which reduced its price target for Kenvue from $20 to $18 while maintaining a “Hold” rating.
While analysts acknowledge Kenvue’s potential, some suggest that alternative investments, particularly in the AI sector, may offer more significant upside and less downside risk.
First Piper 